Outcome of Infusional 5-Fluorouracil, Doxorubicin, and Mitomycin-C (iFAM) Chemotherapy and Analysis of Prognostic Factors in Patients with Refractory Advanced Biliary Tract Cancer

Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy

(2010) Takashi Sasaki et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness

(2010) Sung Yong Oh et al.   INVESTIGATIONAL NEW DRUGS

Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer

(2010) Takashi Sasaki et al.   INVESTIGATIONAL NEW DRUGS

Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine

(2010) Takashi Sasaki et al.   INVESTIGATIONAL NEW DRUGS

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

(2010) Juan Valle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment Efficacy/Safety and Prognostic Factors in Patients with Advanced Biliary Tract Cancer Receiving Gemcitabine Monotherapy: An Analysis of 100 Cases

(2010) Eiichiro Suzuki et al.   ONCOLOGY

Second-Line Treatment With a Combination of Continuous 5-Fluorouracil, Doxorubicin, and Mitomycin-C (Conti-Fam) in Gemcitabine-Pretreated Pancreatic and Biliary Tract Cancer

(2009) Suee Lee et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Prognostic factors and predictive model in patients with advanced biliary tract adenocarcinoma receiving first-line palliative chemotherapy

(2009) Inkeun Park et al.   CANCER

Systemic Therapy for Biliary Tract Cancers

(2008) A. F. Hezel et al.   ONCOLOGIST